This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...

Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...

Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...

References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....

Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

Event features Prime's Health Outcomes team

Forbes

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Zabrina Watkins Our passion Our people “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Traditional Feb. 28, 2025 – denosumab-bmwo (Osenvelt) BLA approval; denosumab-bmwo (Osenvelt) is a biosimilar to reference drug denosumab (Xgeva) RANK ligand inhibitor Osenvelt is indicated for (1)...

Tennessee pharmacies In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were...

Managed Markets Insight & Technology (MMIT)

Home Other Navigation Pharmacy + Providers Commercial Formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...

December 2024 December 2023 June 2024 December 2021 Pharmacy newsletter from Prime Therapeutics that provides information and updates about Prime services. June 2022 Home Other Navigation Pharmacy...

publications Fall 2024 Prime Therapeutics Report October 21, 2024 Debuting a new name and design, the 41st edition of our managed care report still offers the same in-depth industry articles on...

publications Summer 2024 Prime Therapeutics Report June 11, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story...

New approach aligns with long-standing biosimilar strategy

Reimagining pharmacy for our loved ones Please enter a valid video URL. The URL can point to any video file or a Youtube video. View playlist Please enter a valid video URL. The URL can point to...

Expert Clinical Insights Metastatic Melanoma MEDICATION INSIGHTS: Lifileucel (Amtagvi™) The U.S. Food and Drug Administration (FDA) approved lifileucel (Amtagvi™) in February 2024 through the...

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and...

image from Healthcare Advocate Summit Prerak Parikh represented Prime on a panel at Healthcare Advocate Summit 2025 in Las Vegas on Sept. 4 with other payer/PBM professionals Prime Therapeutics At...

Annual conference features presentations, panels, discussions and networking

The American Journal of Managed Care (AJMC): At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection,...

Second annual report gives a transparent overview of Prime’s organizational makeup, highlights milestones along its journey

Hear the first part of a two-part preview of the research the Prime Therapeutics health outcomes team will present at the annual managed care pharmacy event

cover image for MPTR blog Prime expert shares exciting enhancement to Medical Pharmacy Trend Report Lisa Polakowski Lisa Polakowski, PharmD, is the Medical Pharmacy Trend Report director for Prime...

Latest edition of Prime Therapeutics Report spotlights seismic shift in how best to diagnose and manage transthyretin amyloid cardiomyopathy (ATTR-CM) and what it means for patients, providers and...

New indications for approved traditional drugs - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* zopapogene imadenovec-drba Papzimeos Precigen...

AAVRh74var adeno-associated virus serotype Rh74var ABSSSI acute bacterial skin and skin structure infections AChR acetylcholine receptor ADHD attention deficit hyperactivity disorder ALK anaplastic...

New indications for approved gene and cellular therapy products - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* prademagene zamikeracel Zevaskyn...

*Disclaimer: Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product’s manufacturer. All brand names are property of their respective...

Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* diazoxide choline Vykat XR Soleno Hyperphagia in Prader-Willi syndrome (≥ 4 years of age) Oral March...

publications Quarterly Drug Approvals: October 2024 This report provides an overview of new drugs and indications approved in 2024 Generic Name Brand Name Manufacturer Indication(s) Month Approved*...